secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tengjun Biotechnology Corp. (—)
CIK:        0001499785
Form:       8-K/A
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001213900-23-073763
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tengjun Biotechnology restates FY2022 financials; appoints Caihong Qu as interim CEO/CFO after CEO death
--------------------------------------------------------------------------------

- Board concluded FY2022 financial statements should no longer be relied upon due to accounting methodology errors.
- Auditor discovered discrepancies in Q2 review, citing errors in recognition, measurement, and recording.
- Company will amend FY2022 Form 10-K as soon as practicable to correct the errors.
- Caihong Qu, age 48, appointed as director, interim CEO and CFO effective August 10, 2023.
- Qu replaces Xianchang Ma, who passed away on August 3, 2023; she is his late wife.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/ea184679-8ka1_tengjun.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-073763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer